September 2021 - Page 4 of 5 - BioMedWire (BMW)

MondaySep 13, 2021 12:08 pm

An Overview of Ibogaine as an Addiction Treatment

Ibogaine is a compound that is found in a mid-sized shrub known as Tabernanthe iboga, which is native to central-west Africa. Early research and anecdotal evidence suggests that the compound may be used to decrease symptoms of alcohol and drug withdrawal, reduce the risk of recurrent use and ease cravings. The Bwiti religion, practiced in West Central Africa (especially in Gabon, Cameroon as well as the Republic of Congo), uses various parts of the shrub for certain religious (such as during coming of age rituals and welcoming initiates into the religion) and healing purposes, as it possesses anesthetic properties. For example,…

FridaySep 10, 2021 12:20 pm

Four Lifestyle Changes That May Benefit Individuals with Sleep Apnea

Sleep apnea is a common and serious sleep disorder that affects an individual’s breathing during sleep. Undiagnosed and untreated sleep apnea can worsen an individual’s mood, raise their blood pressure and even stress the heart. Some people suffering from this disorder use a device known as a continuous positive airway pressure device, which enables easier breathing. However, making some lifestyle changes may also help sleep apnea patients sleep better. Below are a few changes that may be beneficial to patients with sleep apnea. Avoid some medications Opioids are known to relax the body’s breathing muscles and slow down an individual’s…

FridaySep 10, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview

Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug development On the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled for full commercial launch in Q1 2022 MCUR has successfully synthesized the chemically complex ibogaine and intends to scale up its production during the remainder of 2021 As a diversified life sciences company at the forefront of the mental health industry, Mind Cure Health (CSE:…

FridaySep 10, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Publishes Report Outlining Cannabis Treatments for Conditions Associated with HIV and AIDS

RYAH releases report outlining ways cannabis is being used to treat conditions associated with HIV and AIDS Report data compiled by RYAH Data Ecosystem between January 1, 2018, and August 26, 2021 Data includes specific HIV and AIDS conditions, details cannabis strains used by patients Three-part RYAH Data Ecosystem includes volume control and management devices, QR tracking to identify product formulations and parameters, mobile apps to manage information and provide feedback With a mission to advance remote-health solutions and analytics-based patient treatments across the world, RYAH Group (CSE: RYAH) (formerly RYAH Medtech) is the leader in volume control and management…

ThursdaySep 09, 2021 12:23 pm

New Clinical Guidelines for the Treatment of Brain Tumors Published

Researchers from the Medical University of Vienna have published clinical recommendations for the treatment and diagnosis of brain metastases from solid tumors. These joint recommendations include the latest methods for diagnosis, treatment, prevention and follow-up for brain metastases. They were drafted in partnership with experts from the European Society for Medical Oncology and the European Association of Neuro-Oncology. The experts note that these guidelines are a valuable source of information for physicians and other service providers, as well as patients and their families. The guidelines were published in the “Annals of Oncology” journal. Brain metastasis is common in cancer patients.…

ThursdaySep 09, 2021 11:24 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021 Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13 Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself…

WednesdaySep 08, 2021 1:07 pm

Dog Study May Offer Insight into How Gliomas Impact the Immune System

A recently conducted study has found that in comparison with low-grade gliomas, high-grade gliomas in canines contain more immune cells linked to suppressing immune response. The study adds to evidence suggesting that these tumors may recruit immune cells which assist with immunosuppression. Its findings may be useful in the development of future glioma treatments for both dogs and humans. Gliomas are caused by support cells known as glial cells, which mutate and become cancerous. These cells are usually located throughout the spinal cord and brain. In canines, gliomas make up nearly 35% of all intracranial cancers and are the second…

WednesdaySep 08, 2021 9:30 am

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1st in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium…

WednesdaySep 08, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible…

TuesdaySep 07, 2021 11:07 am

Bladder Cancer Identified Among Most Common Malignancies in Elderly

Oncology is a field of medicine that is focused on the treatment, prevention and diagnosis of cancer. Under this field is genitourinary oncology, a branch that is focused on cancer found in the reproductive system and the urinary system of women and men. The most common types of cancer under this branch include kidney, bladder and prostate cancer, which commonly occur in people aged 55 and above. We discuss them below. Kidney cancer This cancer is often diagnosed when an individual undergoes a test such as an MRI, a CT scan or an ultrasound for illness or pain, including back…